The MPP focuses on increasing access to HIV, hepatitis C and tuberculosis medicines. Since our creation in 2010, we have published a list of priority HIV treatments for our licensing programme. In 2017, we expanded our evaluation to include important treatments for hepatitis C. Our method for prioritising, developed with support from a broad range of experts, is based on four criteria:
Target medicines may include those already in the market as well as investigational candidates. The focus is on medicines that are not yet licensed to the MPP.
The 2017 Prioritization Report selected five HIV and two hepatitis C compounds that, if successfully developed, could improve standard of care for people living in developing countries. The report notes that, given the rapid development of hepatitis C treatments, the foundation will also monitor additional HCV regimens in phase-2 clinical development.
The working paper is a living document. Comments are both welcome and encouraged. Please mail them to firstname.lastname@example.org with subject line “Comments on the 2017 Prioritization Report”
|Rilpivirine (long-acting injectable)|
* The MPP commenced licensing negotiations with the patent holder of bictegravir, Gilead Sciences, in April 2017.
|Ravidasvir (with sofosbuvir)**|
**The MPP signed a licence with Pharco Pharmaceuticals for ravidasvir (21 April 2017).
The status of negotiations on priority products will be updated on a quarterly basis in line with MPP’s Transparency Policy.
In addition, we are monitoring the following four investigational HCV regimens, each with pangenotypic potential: